Updates to the Australian Pharmaceutical Benefits Scheme
22 May 2023
Update
Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.
Amendments have been made to a range of medications on the PBS, including the following medications:
- Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
- Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.
Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.
More news & views
01 August 2025
RANZCP NSW Branch Chair Dr Pramudie Gunaratne awarded AMA Women in Medical Leadership Award
The Royal Australian and New Zealand College of Psychiatrists congratulates New South Wales Branch C...

President's Column July 2025
RANZCP's July President's column from Dr Astha Tomar.
30 July 2025
Best Practice Resources Framework: Contemporary guidance for high-quality clinical practice
A Best Practice Resources Framework – developed to support the diverse and evolving information need...